Double-Refractory CLL: An Oral Option After Two Targeted Therapies Have Already Failed
He's already failed a covalent BTK inhibitor and venetoclax. Pirtobrutinib was built for exactly this sequence — but every subsequent targeted therapy in CLL tends to work for less time than the one before it.
Harold P. and his wife have spent most Friday and Saturday evenings for the past decade on the ballroom dance floor, competing regionally on a seniors' circuit they both take seriously enough to have a coach and a standing rehearsal schedule. He is 74, a retired postal worker, and his CLL has been managed sequentially over eight years: chlorambucil initially, then ibrutinib for four years with a good response, then venetoclax-rituximab after ibrutinib progression, which itself has now progressed after fourteen months.
He is, in the language of the field, double-refractory — a covalent BTK inhibitor and a BCL-2 inhibitor have both been tried and both have failed, leaving a genuinely narrower set of remaining options than he had at diagnosis, and a pattern worth naming directly: his ibrutinib response lasted four years, his venetoclax response fourteen months, each successive line shorter than the one before it.
Pirtobrutinib, a non-covalent BTK inhibitor, was developed specifically to remain active against the resistance mechanisms — most often a BTK C481 mutation — that cause covalent inhibitors like ibrutinib to fail. BRUIN, the trial supporting its approval, enrolled exactly this double-refractory population and reported an overall response rate near 72%, with benefit seen regardless of BTK or PLCG2 mutation status.
What that trial doesn't answer, because no single trial can, is how long a fourth line of targeted therapy holds up in a disease that has, so far, given him a shorter answer every time he's asked it. His performance status remains excellent — he and his wife rehearsed twice this past week despite the relapse news — which is exactly the kind of fitness that keeps a later transplant or CAR-T conversation genuinely on the table rather than academic.
A fourth line, and how long a fourth line tends to last
Start pirtobrutinib. BRUIN showed roughly a 72% overall response rate in exactly this double-refractory population, and the response held regardless of BTK or PLCG2 mutation status. It's an oral, outpatient drug with a manageable toxicity profile — a real option in a situation with few of them left.
I want to name something the response-rate number doesn't capture: each successive line of targeted therapy in this disease has tended to produce shorter responses than the one before — his ibrutinib response lasted four years, his venetoclax response fourteen months. If that pattern holds, pirtobrutinib's own duration may be shorter still.
At 74, his window for pursuing CAR-T or allogeneic transplant narrows every year and with every additional line of disease-directed therapy. I'd want serious consideration of definitive therapy now, while his performance status and disease burden both still favor it, rather than automatically sequencing another oral agent first.
I'm not going to argue against starting pirtobrutinib — BRUIN's data support it regardless of mutation status, so testing doesn't need to gate today's decision.
But I'd send BTK C481 and PLCG2 testing now, in parallel, because it changes what 'the next line after this' looks like. There's real, active investigation into combining pirtobrutinib with venetoclax rechallenge, and knowing his mutation profile now, rather than waiting for a fifth relapse to ask the question, means we're planning ahead rather than reacting each time.
Agreed: start pirtobrutinib now given BRUIN's mutation-independent benefit in this population; send BTK C481 and PLCG2 mutation testing in parallel rather than waiting for the next relapse to ask the question. Formal CAR-T and allogeneic transplant referral held in reserve, to be revisited proactively at his next response assessment rather than only if pirtobrutinib fails.
Not fully agreed: the Transplant Physician's view that transplant evaluation should begin now regardless of pirtobrutinib's outcome, given the narrowing eligibility window with age, versus the CLL Service's preference to see how he responds first. Both positions are documented, with a formal transplant eligibility conversation scheduled regardless, distinct from the treatment decision made today.